Role of novel biological therapies in psoriatic arthritis: Effects on joints and skin

BioDrugs

Volumn 17, Issue 3, 2003, Pages 187-199

  Braun, Juergen ^a   Sieper, Joachim ^b  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; AUTOANTIBODY; AZATHIOPRINE; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; LYMPHOTOXIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANEMIA; ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BIOLOGICAL THERAPY; BRONCHOSPASM; CELL MEMBRANE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEMYELINATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPNEA; GERMANY; GUILLAIN BARRE SYNDROME; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOMA; MILIARY TUBERCULOSIS; NEUROPATHY; NONHUMAN; OPTIC NERVE DISEASE; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; SPINE; T LYMPHOCYTE ACTIVATION; UNITED STATES; VASCULITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038460252     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317030-00005     Document Type: Review

References (110)

1. Gladman DD, Stafford-Brady F, Chang C-H, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990; 17: 809-12
2. Torre-Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991; 30: 245-50
3. Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software; 2001
4. Robert C, Kupper TS. Psoriasis: inflammatory skin diseases, T cells and immune surveillance. N Engl J Med 1999; 341: 1817-28
5. Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518-23
6. Husby G, Williams RC Jr. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1988; 1: 363-71
7. Deleuran BW, Chu CQ, Field M, et al. Localization of interleukin-1α, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 1992; 31: 801-9
8. Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25: 1544-52
9. Nawroth PP, Bank I, Handley D, et al. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1986; 163: 1363-75
10. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; II: 244-7
11. Butler DM, Maini RN, Feldmann M, et al. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti TNF-α antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995; 6: 225-30
12. Haworth C, Brennan FM, Chantry D, et al. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol 1991; 21: 2575-9
13. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322: 547-9
14. Bertolini DR, Nedwin GE, Bringman TS, et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986; 319: 516-8
15. Shinmei M, Masuda K, Kikuchi T, et al. The role of cytokines in chondrocyte mediated cartilage degradation. J Rheumatol 1989; 6 Suppl. 18: 32-4
16. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162: 2163-8
17. Partsch G, Wagner E, Leeb BF, et al. Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 1998; 25: 105-10
18. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992; 35: 1160-9
19. Roux-Lombard P, Punzi L, Hasler F, et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36: 485-9
20. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548-61
21. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993 Dec; 36 (12): 1681-90
22. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994 Oct 22; 344 (8930): 1105-10
23. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994 Oct 22; 344 (8930): 1125-7
24. Maini RN, Elliott MJ, Brennan FM, et al. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 1995 Apr; 144: 195-223
25. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602
26. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) -Fc fusion protein. N Engl J Med 1997; 337: 141-8
27. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93
28. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346-52
29. Brandt J, Haibel H, Reddig J, et al. Treatment of patients with severe ankylosing spondylitis with infliximab: a one year follow up. Arthritis Rheum 2001; 44 (12): 2936-7
30. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a double-blind placebo controlled multicenter trial. Lancet 2002; 359: 1187-93
31. Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000 Jun; 59 (6): 428-33
32. Van den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002; 46: 755-65
33. Stone M, Salonen D, Lax M, et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001 Jul; 28 (7): 1605-14
34. Maksymowych WP, Jhangri GS, Lambert RG, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002; 29: 959-65
35. Antoni C, Dechant C, Ogilvie A, et al. Successful treatment of psoriatic arthritis with infliximab in an MRI controlled study [abstract]. J Rheumatol 2000; 27 Suppl. 59: 24
36. Antoni C, Dechant C, Lorenz HM, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Care Res 2002; 47: 506-12
37. Marzo-Ortega H, McGonagle D, O'Connor P, et al. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001 Sep; 44 (9): 2112-7
38. Gorman JD, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002 May 2; 346 (18): 1349-56
39. Brandt J, Haibel H, Reddig J, et al. Successful treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor α monoclonal antibody infliximab. J Rheumatol 2002; 29: 118-22
40. Van den Bosch F, Kruithof E, De Vos M, et al. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356 (9244): 1821-2
41. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505
42. Mielants H, Veys EM, Goemaere S, et al. A prospective study of patients with spondyloarthropathy with special reference to HLA-B27 and to gut histology. J Rheumatol 1993 Aug; 20 (8): 1353-8
43. Sandborn WJ. Anti-tumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm Bowel Dis 1999; 5: 119-33
44. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001 Nov; 121 (5): 1088-94
45. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001 May; 7 (2): 83-8
46. Lichtenstein GR. Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm Bowel Dis 2001 May; 7 (2): 89-93
47. Krueger GG. Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis. Expert Opin Biol Ther 2002 Apr; 2 (4): 431-41
48. da Silva AJ, Brickelmaier M, Majeau GR, et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2 (+) cells. J Immunol 2002 May 1; 168 (9): 4462-71
49. Lebwohl M, Ali S. Treatment of psoriasis: Part 1. topical therapy and phototherapy. J Am Acad Dermatol 2001 Oct; 45 (4): 487-98
50. Lebwohl M, Ali S. Treatment of psoriasis: Part 2. systemic therapies. J Am Acad Dermatol 2001 Nov; 45 (5): 649-61
51. Krueger GG. Clinical features of psoriatic arthritis. Am J Manag Care 2002 Apr; 8 (6 Suppl.): S160-70
52. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002 Apr; 61 (4): 298-304
53. Ruddle NH. Lymphoid neo-organogenesis: lymphotoxin's role in inflammation and development. Immunol Res 1999; 19: 119-25
54. Barone D, Krantz C, Lambert D, et al. Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion [abstract]. Arthritis Rheum 1999; 42 Suppl.: S90
55. Mease PJ. Cytokine blockers in psoriatic arthritis. Ann Rheum Dis 2001 Nov; 60 Suppl. 3: iii37-40
56. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90
57. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2013-20
58. Felson DT, Andersen JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35
59. Mease PJ, Goffe BS, Metz J, et al. Enbrel® (etanercept) in patients with psoriatic arthritis and psoriasis. Ann Rheum Dis 2001; 60 Suppl. I: 146
60. Mease P, Kivitz A, Burch F, et al. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel®): results of a phase 3 multicenter clinical trial [abstract]. Arthritis Rheum 2001; 44 Suppl.: S90
61. Gottlieb AB, Lowe NJ, Matheson RT, et al. Efficacy of etanercept in patients with psoriasis. Presented at: American Academy of Dermatology; 2002 Feb 24-26; New Orleans (LA)
62. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002; 146: 118-21
63. Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol 2000; 18: 732-4
64. Yazici Y, Erkan D, Lockshin MD. Etanercept in the treatment of severe, resistant psoriatic arthritis: continued efficacy and changing patterns of use after two years [letter]. Clin Exp Rheumatol 2002; 20: 115
65. Elkayam O, Yaron M, Caspi D. From wheels to feet: a dramatic response of severe chronic psoriatic arthritis to etanercept [letter]. Ann Rheum Dis 2000; 59: 839
66. Kurschat P, Rubbert A, Poswig A, et al. Treatment of psoriatic arthritis with etanercept [letter]. J Am Acad Dermatol 2001; 44: 1052
67. Aboulafia DM, Bundow D, Wilske K, et al. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000; 75: 1093-8
68. Kruithof E, Van den Bosch F, Baeten D, et al. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002; 61: 207-12
69. Ogilvie AL, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001 Mar; 144 (3): 587-9
70. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000 May; 42 (5 Pt 1): 829-30
71. Kirby B, Marsland AM, Carmichael AJ, et al. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 2001 Jan; 26 (1): 27-9
72. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001 Jun 9; 357 (9271): 1842-7
73. O'Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol 2002 May; 138 (5): 644-8
74. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002 Jun; 46 (6): 886-91
75. Salvarani C, Cantini F, Olivieri I, et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Care Res 2003. In press
76. Olivieri I, Padula A, Ciancio G, et al. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 2002; 61: 375-6
77. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, editors. Advances in Inflammation Research. Vol 6. New York: Raven Press, 1984: 1-7
78. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001 Oct 11; 345 (15): 1098-104
79. Keane J, Gershon SK, Braun M. Tuberculosis and treatment with infliximab [letter]. N Engl J Med 2002; 346 (8): 625-6
80. Riminton S, Pearce N, Basten A. Tuberculosis and treatment with infliximab [letter]. N Engl J Med 2002; 346 (8): 625
81. Lim WS, Powell RJ, Johnston ID. Tuberculosis and treatment with infliximab. N Engl J Med 2002; 346 (8): 623-6
82. Bean GA, Rosch DR, Briscoe H, et al. Structural deficiences in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol mycobacterium tuberculosis infection. J Immunol 1999; 162: 3504-11
83. Myers A, Clark J, Foster H. Tuberculosis and treatment with infliximab [letter]. N Engl J Med 2002; 346 (8): 625
84. Westendorp RG, Langermans JA, Huizinga TW, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997 Jan 18; 349 (9046): 170-3
85. Ritz MA, Jost R. Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease [letter]. Inflamm Bowel Dis 2001 Nov; 7 (4): 327
86. Smith D, Letendre S. Viral pneumonia as a serious complication of etanercept therapy [letter]. Ann Intern Med 2002 Jan 15; 136 (2): 174
87. Marotte H, Charrin JE, Miossec P. Infliximab-induced aseptic meningitis [letter]. Lancet 2001 Nov 24; 358 (9295): 1784
88. Baghai M, Osmon DR, Wolk DM, et al. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001 Jun; 76 (6): 653-6
89. Zhang Z, Correa H, Bégué RE. Tuberculosis and treatment with infliximab [letter]. N Engl J Med 2002; 346 (8): 624
90. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001 Apr 5; 344 (14): 1099-100
91. Phillips K, Husni ME, Karlson EW, et al. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002 Feb; 47 (1): 17-21
92. De Rosa FG, Bonora S, Di Perri G. Tuberculosis and treatment with infliximab [letter]. N Engl J Med 2002; 346 (8): 624
93. Moreland LW, Cohen SB, Baumgartner SW, et al. Longterm safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238-44
94. Kavanaugh A, Keenan G, DeWoody K, et al. Long-term follow-up of patients treated with Remicade (Infliximab) in clinical trials [abstract]. Arthritis Rheum 2001; 46: S173
95. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 2001 Dec; 45 (6): 953-6
96. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001 Dec; 44 (12): 2862-9
97. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996 Dec; 47 (6): 1531-4
98. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with TNF-α antagonism: by what mechanisms could TNF-α antagonism improve RA but exacerbate multiple sclerosis? Arthritis Rheum 2001; 44: 1977-83
99. Data on file, Centocor
100. FDA website. http://www.fda.gov
101. Bloom BJ. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000 Nov; 43 (11): 2606-8
102. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000 Aug; 27 (8): 2041-4
103. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 2002 Jan; 41 (1): 116-7
104. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002 Feb 16; 359 (9306): 579-80
105. Shergy WJ, Isern RA, Cooley DA, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with RA. J Rheumatol 2002; 29: 667-77
106. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348 (7): 601-8
107. Ellis CN, Krueger GG. Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001 Jul 26; 345 (4): 248-55
108. Dinant HJ, van Kuijk AWR, Goedkoop AY, et al. Alefacept (LFA3-IgG1 fusion protein LFA3TIP) reduces synovial inflammatory infiltrate and improves outcome in psoriatic arthritis. Arthritis Rheum 2001; 42 Suppl.: S91
109. Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002 May; 138 (5): 591-600
110. Krueger JG, Walters IB, Miyazawa M, et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000 Sep; 43 (3): 448-58